1-20 of 122
Paul Workman
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract A066 Acquired resistance to temozolomide in the Th-MYCN mouse as a clinically-relevant platform to evaluate novel therapeutic strategies against high-risk neuroblastoma

Evon Poon, Tong Liang, Giuseppe Barone, Barbara M. Costa, Sara Heuss, Simon P. Robinson, Charles Lin, Paul Workman, Yann Jamin, Louis Chesler
Journal: Cancer Research
Cancer Res (2024) 84 (17_Supplement): A066.
https://doi.org/10.1158/1538-7445.PEDIATRIC24-A066
Published: 05 September 2024
View article titled, Abstract A066 Acquired resistance to temozolomide in the Th-<em>MYCN</em> mouse as a clinically-relevant platform to evaluate novel therapeutic strategies against high-risk neuroblastoma
Journal Articles

Abstract CT111: Pharmacokinetic and pharmacodynamic evaluation of NXP800, a novel GCN2 activator, in a first in human clinical trial

Simon Pacey, Ching Leung, Simon Rodney, Ana Filipa Palma DosReis, Ruth Ruddle, Matthew Tall, Karen Swales, Robert te Poele, Paul Workman, Diane Marsolini, Megan Sardone, Enrique Poradosu, Shay Shemesh, Udai Banerji
Journal: Cancer Research
Cancer Res (2024) 84 (7_Supplement): CT111.
https://doi.org/10.1158/1538-7445.AM2024-CT111
Published: 05 April 2024
View article titled, Abstract CT111: Pharmacokinetic and pharmacodynamic evaluation of NXP800, a novel GCN2 activator, in a first in human clinical trial
Journal Articles

Abstract 6441: Discovery of ARID1A loss as a patient biomarker for NXP800 - A developmental activator of the integrated stress response (ISR) and inhibitor of the HSF1 pathway in ovarian cancer

Robert H. te Poele, Marissa Powers, Swee Sharp, Emmanuel de Billy, Maria Taskinen, Loredana Pellegrino, Sharon Gowan, Asadh Miah, Angela Hayes, Matthew Cheeseman, Keith Jones, Suzanne Eccles, Florence Raynaud, Paul Clarke, Paul Workman
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 6441.
https://doi.org/10.1158/1538-7445.AM2024-6441
Published: 22 March 2024
View article titled, Abstract 6441: Discovery of ARID1A loss as a patient biomarker for NXP800 - A developmental activator of the integrated stress response (ISR) and inhibitor of the HSF1 pathway in ovarian cancer
Journal Articles

Abstract 524: Using acquired resistance to explore the mechanism of action of the integrated stress response/GCN2 activator NXP800 - A new developmental agent for platinum-resistant ARID1A mutant ovarian cancer

Marissa V. Powers, Rachel Hodgson, Swee Y. Sharp, Toby Roe, K. Elizabeth Allen, Susan Campbell, Robert te Poele, Matthew Cheeseman, Keith Jones, Paul A. Clarke, Paul Workman
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 524.
https://doi.org/10.1158/1538-7445.AM2024-524
Published: 22 March 2024
View article titled, Abstract 524: Using acquired resistance to explore the mechanism of action of the integrated stress response/GCN2 activator NXP800 - A new developmental agent for platinum-resistant ARID1A mutant ovarian cancer
Journal Articles

Abstract 3542: The Chemical Probes Portal: An essential resource providing expert advice on chemical tools for cancer research

Domenico Sanfelice, Albert Antolin, Alisa Crisp, Yi Chen, Paul Brennan, Susanne Müller, Bissan Al-Lazikani, Aled Edwards, Paul Workman
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 3542.
https://doi.org/10.1158/1538-7445.AM2024-3542
Published: 22 March 2024
View article titled, Abstract 3542: The Chemical Probes Portal: An essential resource providing expert advice on chemical tools for cancer research
Journal Articles

Abstract PR-002: Activation of the integrated stress response by NXP800, an orally available, clinical-stage, investigational agent in ARID1A-mutated, platinum resistant ovarian cancer

Marissa V. Powers, Swee Y. Swap, Robert te Poele, Eirini-Maria Lampraki, Toby Roe, Loredana Pellegrino, Maria Taskinen, Suzenne Eccles, Florence Raynaud, Matthew Cheeseman, Keith Jones, Paul A. Clarke, Paul Workman
Journal: Cancer Research
Cancer Res (2024) 84 (5_Supplement_2): PR-002.
https://doi.org/10.1158/1538-7445.OVARIAN23-PR-002
Published: 04 March 2024
View article titled, Abstract PR-002: Activation of the integrated stress response by NXP800, an orally available, clinical-stage, investigational agent in ARID1A-mutated, platinum resistant ovarian cancer
Journal Articles

The NCI-60 Human Tumor Cell Line Screen: A Catalyst for Progressive Evolution of Models for Discovery and Development of Cancer Drugs

Paul Workman
Journal: Cancer Research
Cancer Res (2023) 83 (19): 3170–3173.
https://doi.org/10.1158/0008-5472.CAN-23-2612
Published: 02 October 2023
View article titled, The NCI-60 Human Tumor Cell Line Screen: A Catalyst for Progressive Evolution of Models for Discovery and Development of Cancer Drugs
Open the PDF for The NCI-60 Human Tumor Cell Line Screen: A Catalyst for Progressive Evolution of Models for Discovery and Development of Cancer Drugs in another window
Journal Articles

Abstract LB234: Activation of the integrated stress response by the developmental HSF1 pathway inhibitor NXP800

Marissa V. Powers, Swee Y. Sharp, Eirini-Maria Lampraki, Toby Roe, Loredana Pellegrino, Maria Taskinen, Robert te Poele, Florence Raynaud, Suzanne Eccles, Matthew Cheeseman, Keith Jones, Paul A. Clarke, Paul Workman
Journal: Cancer Research
Cancer Res (2023) 83 (8_Supplement): LB234.
https://doi.org/10.1158/1538-7445.AM2023-LB234
Published: 14 April 2023
View article titled, Abstract LB234: Activation of the integrated stress response by the developmental HSF1 pathway inhibitor NXP800
Journal Articles

Abstract 2807: HER3 is an actionable target in advanced prostate cancer

Susana Miranda, Veronica Gil, Ruth Riisnaes, Bora Gurel, Mariantonietta D’Ambrosio, Alessandro Vasciaveo, Mateus Crespo, Ana Ferreira, Daniela Brina, Martina Troiani, Adam Sharp, Beshara Sheehan, Rossitza Christova, George Seed, Ines Figueiredo, Maryou Lambros, David Dolling, Jan Rekowski, Abdullah Alajati, Matthew Clarke, Rita Pereira, Penny Flohr, Gemma Fowler, Gunther Boysen, Semini Sumanasuriya, Diletta Bianchini, Pasquale Rescigno, Caterina Aversa, Nina Tunariu, Christina Guo, Alec Paschalis, Claudia Bertan, Lorenzo Buroni, Jian Ning, Suzanne Carreira, Paul Workman, Amanda Swain, Andrea Califano, Michael M. Shen, Andrea Alimonti, Antje Neeb, SU2C/PCF International Prostate Cancer Dream Team, Jonathan Welti, Wei Yuan, Johann de Bono
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 2807.
https://doi.org/10.1158/1538-7445.AM2022-2807
Published: 15 June 2022
View article titled, Abstract 2807: HER3 is an actionable target in advanced prostate cancer
Journal Articles

Abstract ND08: NXP800: A first-in-class orally active, small-molecule HSF1 pathway inhibitor

Paul Workman
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): ND08.
https://doi.org/10.1158/1538-7445.AM2022-ND08
Published: 15 June 2022
View article titled, Abstract ND08: NXP800: A first-in-class orally active, small-molecule HSF1 pathway inhibitor
Journal Articles

Abstract 6355: A characterisation of direct and indirect transcription factor inhibition to target brachyury in chordoma

Hadley E. Sheppard, Alessandra Dall’Agnese, Woojun D. Park, M. Shamim Shamim, Julien Dubrulle, Hannah L. Johnson, Fabio Stossi, Josh Sommer, Joan Levy, Tanaz Sharifnia, Mathias Wawer, Behnam Nabet, Paul A. Clemons, Stuart L. Schreiber, Paul Clarke, Rick Young, Charles Y. Lin, Paul Workman
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 6355.
https://doi.org/10.1158/1538-7445.AM2022-6355
Published: 15 June 2022
View article titled, Abstract 6355: A characterisation of direct and indirect transcription factor inhibition to target brachyury in chordoma
Journal Articles

HER3 Is an Actionable Target in Advanced Prostate Cancer

Veronica Gil, Susana Miranda, Ruth Riisnaes, Bora Gurel, Mariantonietta D’Ambrosio, Alessandro Vasciaveo, Mateus Crespo, Ana Ferreira, Daniela Brina, Martina Troiani, Adam Sharp, Beshara Sheehan, Rossitza Christova, George Seed, Ines Figueiredo, Maryou Lambros, David Dolling, Jan Rekowski, Abdullah Alajati, Matthew Clarke, Rita Pereira, Penny Flohr, Gemma Fowler, Gunther Boysen, Semini Sumanasuriya, Diletta Bianchini, Pasquale Rescigno, Caterina Aversa, Nina Tunariu, Christina Guo, Alec Paschalis, Claudia Bertan, Lorenzo Buroni, Jian Ning, Suzanne Carreira, Paul Workman, Amanda Swain, Andrea Califano, Michael M. Shen, Andrea Alimonti, Antje Neeb, PCF/SU2C International Prostate Cancer Dream Team, Jonathan Welti, Wei Yuan, Johann de Bono
Journal: Cancer Research
Cancer Res (2021) 81 (24): 6207–6218.
https://doi.org/10.1158/0008-5472.CAN-21-3360
Published: 15 December 2021
View article titled, HER3 Is an Actionable Target in Advanced Prostate Cancer
Open the PDF for HER3 Is an Actionable Target in Advanced Prostate Cancer in another window
Includes: Supplementary data
Journal Articles

Abstract LB216: Targeted brachyury degradation disrupts a highly specific autoregulatory program controlling chordoma cell identity

Hadley E. Sheppard, Alessandra Dall'Agnese, Woojun D. Park, Hamza Shamim, Julien Dubrulle, Hannah L. Johnson, Fabio Stossi, Patricia Cogswell, Josh Sommer, Joan Levy, Tanaz Sharifnia, Mathias J. Wawer, Paul A. Clemons, Behnam Nabet, Nathanael S. Gray, Stuart L. Schreiber, Paul Workman, Richard A. Young, Charles Y. Lin
Journal: Cancer Research
Cancer Res (2021) 81 (13_Supplement): LB216.
https://doi.org/10.1158/1538-7445.AM2021-LB216
Published: 01 July 2021
View article titled, Abstract LB216: Targeted brachyury degradation disrupts a highly specific autoregulatory program controlling chordoma cell identity
Journal Articles

CHK1 Inhibition Is Synthetically Lethal with Loss of B-Family DNA Polymerase Function in Human Lung and Colorectal Cancer Cells

Rebecca F. Rogers, Michael I. Walton, Daniel L. Cherry, Ian Collins, Paul A. Clarke, Michelle D. Garrett, Paul Workman
Journal: Cancer Research
Series: Author Choice
Cancer Res (2020) 80 (8): 1735–1747.
https://doi.org/10.1158/0008-5472.CAN-19-1372
Published: 15 April 2020
View article titled, CHK1 Inhibition Is Synthetically Lethal with Loss of B-Family DNA Polymerase Function in Human Lung and Colorectal Cancer Cells
Open the PDF for CHK1 Inhibition Is Synthetically Lethal with Loss of B-Family DNA Polymerase Function in Human Lung and Colorectal Cancer Cells in another window
Includes: Supplementary data
Journal Articles

Correction: Silencing of HSP90 Cochaperone AHA1 Expression Decreases Client Protein Activation and Increases Cellular Sensitivity to the HSP90 Inhibitor 17-Allylamino-17-Demethoxygeldanamycin

Joanna L. Holmes, Swee Y. Sharp, Steve Hobbs, Paul Workman
Journal: Cancer Research
Cancer Res (2019) 79 (1): 286.
https://doi.org/10.1158/0008-5472.CAN-18-3577
Published: 02 January 2019
View article titled, Correction: Silencing of HSP90 Cochaperone AHA1 Expression Decreases Client Protein Activation and Increases Cellular Sensitivity to the HSP90 Inhibitor 17-Allylamino-17-Demethoxygeldanamycin
Open the PDF for Correction: Silencing of HSP90 Cochaperone AHA1 Expression Decreases Client Protein Activation and Increases Cellular Sensitivity to the HSP90 Inhibitor 17-Allylamino-17-Demethoxygeldanamycin in another window
Journal Articles

Correction: In vitro Biological Characterization of a Novel, Synthetic Diaryl Pyrazole Resorcinol Class of Heat Shock Protein 90 Inhibitors

Swee Y. Sharp, Kathy Boxall, Martin Rowlands, Chrisostomos Prodromou, S. Mark Roe, Alison Maloney, Marissa Powers, Paul A. Clarke, Gary Box, Sharon Sanderson, Lisa Patterson, Thomas P. Matthews, Kwai-Ming J. Cheung, Karen Ball, Angela Hayes, Florence Raynaud, Richard Marais, Laurence Pearl, Sue Eccles, Wynne Aherne, Edward McDonald, Paul Workman
Journal: Cancer Research
Cancer Res (2019) 79 (1): 287.
https://doi.org/10.1158/0008-5472.CAN-18-3578
Published: 02 January 2019
View article titled, Correction: <em>In vitro</em> Biological Characterization of a Novel, Synthetic Diaryl Pyrazole Resorcinol Class of Heat Shock Protein 90 Inhibitors
Open the PDF for Correction: <em>In vitro</em> Biological Characterization of a Novel, Synthetic Diaryl Pyrazole Resorcinol Class of Heat Shock Protein 90 Inhibitors in another window
Journal Articles

Abstract 4977: MIR1307 mediates pancreatic cancer resistance to FOLFIRINOX chemotherapy by affecting response to DNA damage

Pietro Carotenuto, Domenico Zito, Maria C. Previdi, Maya Raj, Matteo Fassan, Andrea Lampis, Francesco Scalafani, Andrea Lanese, Ian Said-Huntingford, Jens C. Hahne, Kate Young, Ruwaida Begum, Zakaria Ethiar, Andrew Wotherspoon, Naureen Starling, Anguraj Sadanandam, David Cunningham, Ian Chau, Paul Workman, Rajesh Chopra, Nicola Valeri, Chiara Braconi
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): 4977.
https://doi.org/10.1158/1538-7445.AM2018-4977
Published: 01 July 2018
View article titled, Abstract 4977: MIR1307 mediates pancreatic cancer resistance to FOLFIRINOX chemotherapy by affecting response to DNA damage
Journal Articles

Abstract 2896: A genome-wide CRISPR/Cas9 pooled screen identifies EML4-ALK variant-specific synthetic lethal partners of HSP90 inhibitors

Marco P. Licciardello, Paul A. Clarke, Paul Workman
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): 2896.
https://doi.org/10.1158/1538-7445.AM2018-2896
Published: 01 July 2018
View article titled, Abstract 2896: A genome-wide CRISPR/Cas9 pooled screen identifies EML4-ALK variant-specific synthetic lethal partners of HSP90 inhibitors
Journal Articles

Abstract 2976: Confirmation of in-cell target engagement using the proteolysis targeting chimeras (PROTACs) against pirin

Swee Y. Sharp, Nicola E. Chessum, John J. Caldwell, Marissa V. Powers, A Elisa Pasqua, Birgit Wilding, Ian Collins, Bugra Ozer, Martin Rowlands, Mark Stubbs, Rosemary Burke, Rob L. van Montfort, Matthew D. Cheeseman, Paul A. Clarke, Paul Workman, Keith Jones
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): 2976.
https://doi.org/10.1158/1538-7445.AM2018-2976
Published: 01 July 2018
View article titled, Abstract 2976: Confirmation of in-cell target engagement using the proteolysis targeting chimeras (PROTACs) against pirin
Journal Articles

Abstract 293: Screening the druggable genome for synthetic lethal interactions with the CHK1 inhibitor PNT737

Rebecca Rogers, Mike I. Walton, Paul Clarke, Ian Collins, Michelle D. Garrett, Paul Workman
Journal: Cancer Research
Cancer Res (2017) 77 (13_Supplement): 293.
https://doi.org/10.1158/1538-7445.AM2017-293
Published: 01 July 2017
View article titled, Abstract 293: Screening the druggable genome for synthetic lethal interactions with the CHK1 inhibitor PNT737